Annual report pursuant to Section 13 and 15(d)

Subsequent Events

Subsequent Events
12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 14 – Subsequent Events


On March 3, 2022, the Company settled a case filed by Jeffrey Lions and Daniel Vallera and paid $0.4 million in full and final settlement (see Note 9).


The Company has entered into a sublease with Aimmune Therapeutics, Inc. for 4,500 square feet of office space located in Brisbane, CA having a commencement date of January 1, 2022 and maturing on June 30, 2024


On February 11, 2022, 60,855 shares of issuable common stock were converted into an equal number of shares of common stock.